Sub Banner Image

Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion

Markets

Naomi Kresge, Gerry Smith

·

June 17, 2025

·

Bloomberg

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term growth.

More from

Bloomberg

More

Markets

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.